Overview

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers

Status:
Completed
Trial end date:
2018-09-18
Target enrollment:
Participant gender:
Summary
This single-center, open-label study will evaluate the pharmacokinetics, safety, and tolerability of emicizumab following a single subcutaneous (SC) administration to healthy Chinese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche